March 13, 2024 - Cancer-related trials contact form · Phone: 855-776-0015 (toll-free)

January 17, 2018 - (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available small molecule inhibitor of the IRAK4 ...

November 28, 2023 - Christian Grommes, Han Tun, Allison ... Grzegorz S. Nowakowski; Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies....

January 7, 2022 - CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.

May 1, 2023 - We propose interleukin-1 receptor-associated kinase-4 (IRAK-4) as a potential target across these diseases and describe the activity and mechanism of oral IRAK-4 inhibitor CA-4948.Experimental Design:. Human primary central nervous system lymphoma (PCNSL) and melanoma brain metastases (MBM) ...

December 7, 2020 - CA-4948-101 is a phase I trial dose escalation trial with a 3 + 3 design. Seven dosing cohorts were assessed including 50 and 100 mg daily (QD), and 50, 100, 200, 300, or 400 mg twice daily (BID) continuous oral monotherapy in 21-day cycles. Objectives included safety and tolerance (primary), ...

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene's compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines. Inhibition of TLR ...

February 20, 2020 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

National Cancer Institute at the National Institutes of Health

November 13, 2019 - Introduction and PurposeIRAK4 kinase activity is essential for signaling downstream of toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) fam

November 10, 2020 - Under the CRADA, Curis will collaborate with the NCI Cancer Therapy Evaluation Program to conduct non-clinical and clinical studies of Curis's proprietary compound CA-4948, an IRAK-4 kinase inhibitor that acts as a Toll-like Receptor (TLR) suppressor, as an anti-cancer agent.

December 9, 2020 - - Reduction of marrow blasts observed in all evaluable patients - - Marrow complete response observed in 2 patients - - Management to host virtual KOL event today, Tuesday, December 8 at 8:00 a.m. ET -

December 8, 2020 - Curis (NASDAQ:CRIS) soars 141% premarket in reaction to positive preliminary data from its ongoing single arm Phase 1 dose escalation study of orally...